NDA 018035 · Jubilant
Draximage Mdp-10
Technetium Tc-99m Medronate · Injection
Last checked: Nov 20, 2026Latest source record: May 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1978
Nov 28, 1978
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
2 Phase 3, 0 recruiting
FAERS reports
2
2 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 5, 2025.
INDICATIONS AND USAGE MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate) may be used as a bone imaging agent to delineate areas of altered osteogenesis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 28, 1978 Original approval · Type 5 - New Formulation or New Manufacturer Review
2 products under this application
- DRAXIMAGE MDP-10 · TECHNETIUM TC-99M MEDRONATE N/A · INJECTABLE, INJECTION · Discontinued
- DRAXIMAGE MDP-25 · TECHNETIUM TC-99M MEDRONATE N/A · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Technetium Tc-99m Medronate" as an intervention, any sponsor and status, largest first.
- Diagnostic Performance and Safety of 18F-NaF-PET/CT in Bone Metastases Compared With 99mTc⁃MDP-BS±SPECTPivotal-lookingCompleted
HTA Co., Ltd.Industry
NCT05614518 · 280 participants · Start Mar 29, 2021 · Primary completion Jun 2, 2022
Drug: Sodium Fluoride F-18 Injection; Technetium[99mTc] Methylenediphosphonate Injection · For: Bone Metastases
Sites: Beijing, China
Stanford UniversityAcademic, hospital or other
NCT00375830 · 114 participants · Start Jan 2006 · Primary completion Apr 17, 2017
Drug: 99mTc-methyl diphosphonate; 18F-Fludeoxyglucose (18F-FDG) and 4 more · For: Cancer
Sites: Stanford, California
- Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99MoPivotal-lookingTerminated
University of ManitobaAcademic, hospital or other
NCT03002454 · 4 participants · Start Aug 2016 · Primary completion Nov 2016
Drug: 99mTc MDP Injection:neutron-bombardment · For: Cancer of Bone
Sites: Winnipeg, Canada
- Efficacy of Ra-223 in PSMA PET Optimally Selected PatientsActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT05924672 · 2 participants · Start Aug 30, 2024 · Primary completion Jan 7, 2026
Drug: Radium-223; Technetium Tc 99M Medronate · For: Castration-Resistant Prostate Carcinoma; Metastatic Malignant Neoplasm in the Bone; Stage IVB Prostate Cancer AJCC v8
Sites: San Francisco, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chills1
- dysphagia1
- eye oedema1
- eye pain1
- hypoaesthesia1
- mucosal inflammation1
- stomatitis1
- visual impairment1
- vomiting1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Influence of exercise on the distribution of technetium Tc 99m medronate following intra-articular injection in horses.
Dulin JA, Drost WT, Phelps MA, et al. · Am J Vet Res 2012 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Jubilant · Also marketed as Draximage Mdp-25
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.